Potential Mylan (MYL)/Upjohn (PFE) Merger a 'Goldilocks Scenario' - Mizuho

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. ACN
3. NVDA
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. HOOD
10. MSFT

Go back to Potential Mylan (MYL)/Upjohn (PFE) Merger a 'Goldilocks Scenario' - Mizuho

UPDATE: Pfizer (PFE) Tops Q2 EPS by 5c, Revenues Miss; Lowers FY19 EPS/Revenue Guidance

July 29, 2019 6:51 AM EDT

(Updated - July 29, 2019 6:54 AM EDT)

Pfizer (NYSE: PFE) reported Q2 EPS of $0.80, $0.05 better than the analyst estimate of $0.75. Revenue for the quarter came in at $13.26 billion versus the consensus estimate of $13.4 billion.

Second-Quarter 2019 Revenues of $13.3 Billion, Reflecting 2% Operational Growth Driven by 6% Operational Growth from Pfizer Biopharmaceuticals GroupSecond-Quarter 2019 Reported Diluted EPS(1) of $0.89, Adjusted Diluted EPS(2) of $0.80Updated 2019 Financial Guidance Primarily to Reflect the Anticipated August 1, 2019 Formation of the Consumer Healthcare Joint Venture with GlaxoSmithKline plc(3) and the Anticipated Near-Term Completion of the Array BioPharma Inc. AcquisitionAnnounces Reverse Morris Trust... More

Mylan (MYL) in Talks to Merge with Pfizer's (PFE) Off-Patent Drug Business - Reports

July 28, 2019 11:42 AM EDT

Mylan (NASDAQ: MYL) shares will be on watch Monday amid reports the company is in talks to merge with Pfizer's (NYSE: PFE) off-patent drug unit in a stock deal.

Mylan shareholders would receive a little more than 40% of... More